[{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Lisaftoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Ascentage Pharma"},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"Avenzo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allorion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allorion Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Allorion Therapeutics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"Zhejiang Cancer Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Zhejiang Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Cancer Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Cancer Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"Samsung Medical Center","sponsor":"Korean Cancer Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Samsung Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Medical Center \/ Korean Cancer Study Group","highestDevelopmentStatusID":"8","companyTruncated":"Samsung Medical Center \/ Korean Cancer Study Group"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MSN Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MSN Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Region \u00d6rebro County","sponsor":"University of Patras | University of Florence | Azienda USL Toscana Centro | Helsinki University Central Hospital | Institute for Medical Technology Assessment - the Netherlands | Security Labs Consulting Limited | Circular Economy Foundation | Universida","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"Region \u00d6rebro County","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Region \u00d6rebro County \/ University of Patras | University of Florence | Azienda USL Toscana Centro | Helsinki University Central Hospital | Institute for Medical Technology Assessment - the Netherlands | Security Labs Consulting Limited | Circular Economy Foundation | Universida","highestDevelopmentStatusID":"10","companyTruncated":"Region \u00d6rebro County \/ University of Patras | University of Florence | Azienda USL Toscana Centro | Helsinki University Central Hospital | Institute for Medical Technology Assessment - the Netherlands | Security Labs Consulting Limited | Circular Economy Foundation | Universida"},{"orgOrder":0,"company":"Royal Marsden NHS Foundation Trust","sponsor":"Pfizer Inc | AstraZeneca | Institute of Cancer Research, United Kingdom | UNICANCER | Gustave Roussy | Invitae","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Royal Marsden NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Royal Marsden NHS Foundation Trust \/ Pfizer Inc | AstraZeneca | Institute of Cancer Research, United Kingdom | UNICANCER | Gustave Roussy | Invitae","highestDevelopmentStatusID":"8","companyTruncated":"Royal Marsden NHS Foundation Trust \/ Pfizer Inc | AstraZeneca | Institute of Cancer Research, United Kingdom | UNICANCER | Gustave Roussy | Invitae"},{"orgOrder":0,"company":"Royal Marsden NHS Foundation Trust","sponsor":"Pfizer Inc | Breast Cancer Now","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Royal Marsden NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal Marsden NHS Foundation Trust \/ Pfizer Inc | Breast Cancer Now","highestDevelopmentStatusID":"6","companyTruncated":"Royal Marsden NHS Foundation Trust \/ Pfizer Inc | Breast Cancer Now"},{"orgOrder":0,"company":"biotx.ai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"biotx.ai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"biotx.ai \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"biotx.ai \/ Undisclosed"},{"orgOrder":0,"company":"International Cancer Research Group, United Arab Emirates","sponsor":"King Saud Medical City | Max-Planck-Institut f\u00fcr Quantenoptik (MPQ), and Faculty of Physics at Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen (LMU), Garching, Germany | King Abdallah University for Science and Technology (KAUST), Thuwal, Saudi Arabia.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.A.E","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"International Cancer Research Group, United Arab Emirates","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Cancer Research Group, United Arab Emirates \/ King Saud Medical City | Max-Planck-Institut f\u00fcr Quantenoptik (MPQ), and Faculty of Physics at Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen (LMU), Garching, Germany | King Abdallah University for Science and Technology (KAUST), Thuwal, Saudi Arabia.","highestDevelopmentStatusID":"8","companyTruncated":"International Cancer Research Group, United Arab Emirates \/ King Saud Medical City | Max-Planck-Institut f\u00fcr Quantenoptik (MPQ), and Faculty of Physics at Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen (LMU), Garching, Germany | King Abdallah University for Science and Technology (KAUST), Thuwal, Saudi Arabia."},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc | Joseph Sanchez Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Suspension","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc | Joseph Sanchez Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc | Joseph Sanchez Foundation"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Fundacion Oncosur","sponsor":"Pfizer Inc | Apices Soluciones | Pierre Fabre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHILE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fundacion Oncosur","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundacion Oncosur \/ Pfizer Inc | Apices Soluciones | Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"Fundacion Oncosur \/ Pfizer Inc | Apices Soluciones | Pierre Fabre"},{"orgOrder":0,"company":"Megalabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Megalabs","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Megalabs \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Megalabs \/ Undisclosed"},{"orgOrder":0,"company":"Criterium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Criterium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Criterium \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Criterium \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Palbociclib","moa":"||Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Camizestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Camizestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Camizestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"||Glutaminase kidney isoform, mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Paradigm BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Palazestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Olema Oncology","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Olema Oncology \/ Paradigm BioCapital","highestDevelopmentStatusID":"10","companyTruncated":"Olema Oncology \/ Paradigm BioCapital"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Palazestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Olema Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Olema Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palazestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Olema Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Olema Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palazestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Olema Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Olema Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Olema Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Palazestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Olema Oncology","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Olema Oncology"},{"orgOrder":0,"company":"Arvinas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2020","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Undisclosed"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2021","type":"Collaboration","leadProduct":"Vepdegestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":2.0499999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.0499999999999998,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2021","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Relay Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relay Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Relay Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relay Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Relay Therapeutics \/ Nextech","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Nextech"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foundation Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Onapristone","moa":"||Progesterone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Menarini","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Alphamab Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"KN026","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Alphamab Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Alphamab Oncology"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Fulvestrant","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zymeworks \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Pfizer Inc"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zymeworks \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Undisclosed"},{"orgOrder":0,"company":"Celcuity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"||Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/ Undisclosed"},{"orgOrder":0,"company":"Celcuity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"||Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/ Undisclosed"},{"orgOrder":0,"company":"Celcuity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"||Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/ Undisclosed"},{"orgOrder":0,"company":"Celcuity","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Gedatolisib","moa":"||Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"IND Enabling","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celcuity \/ Pfizer Inc","highestDevelopmentStatusID":"5","companyTruncated":"Celcuity \/ Pfizer Inc"},{"orgOrder":0,"company":"Celcuity","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Gedatolisib","moa":"||Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celcuity \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/ Undisclosed"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TTI-101","moa":"||STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tvardi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TTI-101","moa":"||STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tvardi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2025","type":"Collaboration","leadProduct":"Vepdegestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":2.0499999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.0499999999999998,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series B Financing","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ OrbiMed"}]

Find Clinical Drug Pipeline Developments & Deals for Palbociclib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Palbociclib,Fulvestrant

                          Therapeutic Area : Oncology

                          Study Phase : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : PRIMCYV® is a targeted therapy containing the active constituent palbociclib, a first-in-class CDK 4/6 inhibitor indicated in combination with an aromatase inhibitor for the first-line treatment of adult patients with HR+, HER2- metastatic breast cancer...

                          Product Name : Primcyv

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 13, 2023

                          Lead Product(s) : Palbociclib,Fulvestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          02

                          Lead Product(s) : Amcenestrant,Palbociclib

                          Therapeutic Area : Oncology

                          Study Phase : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : The pivotal study (AMEERA-3) of amcenestrant versus physician’s choice in locally advanced or metastatic estrogen receptor-positive (ER+) breast cancer is fully recruited; readout expected in H2 2021.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 19, 2021

                          Lead Product(s) : Amcenestrant,Palbociclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          03

                          Lead Product(s) : Fulvestrant,Palbociclib

                          Therapeutic Area : Oncology

                          Study Phase : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Dr. Reddy’s Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe is available in a carton containing two 5 mL single-dose prefilled syringes.

                          Product Name : Fulvestrant-Generic

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 07, 2020

                          Lead Product(s) : Fulvestrant,Palbociclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          04

                          Lead Product(s) : Amcenestrant,Palbociclib

                          Therapeutic Area : Oncology

                          Study Phase : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Company going to present clinical data on its oncology portfolio including data on its Phase 1/2 study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/HER2- metastatic breast cancer.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 13, 2020

                          Lead Product(s) : Amcenestrant,Palbociclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          05

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Thew proceeds will be used to advance Avenzo’s portfolio of potential best-in-class oncology drug candidates, including AVZO-021, the company’s lead drug candidate.

                          Product Name : AVZO-021

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          September 22, 2025

                          Lead Product(s) : AVZO-021,Palbociclib,Fulvestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : OrbiMed

                          Deal Size : $60.0 million

                          Deal Type : Series B Financing

                          blank

                          06

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : The collaboration aims for the co-development of ARV-471 (vepdegestrant), an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader.

                          Product Name : ARV-471

                          Product Type : PROTACs

                          Upfront Cash : $650.0 million

                          September 17, 2025

                          Lead Product(s) : Vepdegestrant,Palbociclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Pfizer Inc

                          Deal Size : $2,050.0 million

                          Deal Type : Collaboration

                          blank

                          07

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Itovebi (inavolisib) is a kinase inhibitor indicated with palbociclib for treating endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer.

                          Product Name : Itovebi

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 23, 2025

                          Lead Product(s) : Inavolisib,Palbociclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : AZD9833 (camizestrant) is an investigational, potent, next-generation oral SERD and ER antagonist that is currently being investigated for the treatment of HR-positive breast cancer.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 26, 2025

                          Lead Product(s) : Camizestrant,Palbociclib,Ribociclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : GDC-0077 (inavolisib) is a PI3K alpha Inhibitor in combination with palbociclib and fulvestran, which is currently being evaluated for the treatment of HR+/HER2-breast Cancer.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 27, 2025

                          Lead Product(s) : Inavolisib,Fulvestrant,Palbociclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : RLY-2608 is a PI3K alpha inhibitor, small molecule, which is being evaluated for the treatment of patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 11, 2024

                          Lead Product(s) : RLY-2608,Fulvestrant,Palbociclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank